| |
| |
|
| Insider
Information: |
Aselage Steve |
| Relationship: |
Director |
| City: |
Fremont |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
293,421 |
|
|
Indirect Shares
|
22,000 |
|
|
| Direct
Value |
$7,031,645 |
|
|
|
Indirect Value
|
$169,660 |
|
|
| Total
Shares |
315,421 |
|
|
| Total
Value |
$7,201,305 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
5
|
5
|
|
Stock
price went up :
|
1
|
3
|
| Stock
price went down : |
4
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
1.5
|
| Percentage
Gain/Loss : |
 -23.4%
|
 62.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Cti Biopharma Corporation |
CTIC |
EVP, Global Commercial... |
2005-06-30 |
24,133 |
2004-08-03 |
0 |
Premium* |
|
|
Biomarin Pharmaceutical Inc |
BMRN |
EVP, Chief Business Of... |
2012-07-02 |
59,030 |
2006-04-28 |
0 |
Premium* |
|
|
Travere Therapeutics, Inc |
TVTX |
Director |
2022-05-11 |
146,919 |
2021-11-05 |
19,500 |
Premium* |
|
|
Acer Therapeutics Inc |
ACER |
Director |
2023-11-17 |
0 |
2017-09-19 |
0 |
Premium* |
|
|
Biocryst Pharmaceuticals Inc |
BCRX |
Director |
2024-05-24 |
63,339 |
2024-05-24 |
2,500 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
170 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Dev |
• – – |
2009-04-30 |
4 |
A |
$10.93 |
$16,560 |
D/D |
1,515 |
33,916 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Dev. |
• – – |
2008-04-30 |
4 |
B |
$10.37 |
$15,825 |
D/D |
1,526 |
33,560 |
2.74 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2010-04-30 |
4 |
A |
$11.64 |
$17,827 |
D/D |
1,532 |
21,387 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2011-04-29 |
4 |
A |
$11.64 |
$18,583 |
D/D |
1,597 |
31,478 |
0 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2020-03-01 |
4 |
A |
$3.00 |
$4,998 |
D/D |
1,666 |
25,092 |
0 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2019-09-01 |
4 |
A |
$2.99 |
$4,999 |
D/D |
1,672 |
6,672 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Executive Officer |
• • – |
2018-11-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,750 |
251,533 |
0 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2019-12-01 |
4 |
A |
$2.85 |
$4,999 |
D/D |
1,754 |
23,426 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2019-05-14 |
4 |
AS |
$17.79 |
$32,698 |
D/D |
(1,838) |
257,804 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2019-05-15 |
4 |
AS |
$17.82 |
$32,753 |
D/D |
(1,838) |
255,966 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Ops |
• – – |
2006-10-31 |
4 |
B |
$6.92 |
$12,939 |
D/D |
1,870 |
2,829 |
2.74 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2020-11-30 |
4 |
A |
$5.11 |
$9,995 |
D/D |
1,956 |
30,569 |
0 |
- |
|
| ACER |
Acer Therapeutics Inc |
Director |
– • – |
2017-12-14 |
4 |
B |
$12.00 |
$24,000 |
D/D |
2,000 |
13,905 |
2.39 |
- |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2019-03-12 |
4 |
B |
$8.30 |
$16,600 |
D/D |
2,000 |
2,000 |
2.39 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2019-05-08 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
259,642 |
0 |
- |
|
| ACER |
Acer Therapeutics Inc |
Director |
– • – |
2021-12-09 |
4 |
B |
$2.15 |
$4,334 |
D/D |
2,016 |
65,921 |
2.31 |
% |
|
| BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Dev |
• – – |
2007-04-30 |
4 |
B |
$6.92 |
$14,295 |
D/D |
2,066 |
4,895 |
2.74 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Dev |
• – – |
2007-10-31 |
4 |
AB |
$6.92 |
$14,800 |
D/D |
2,139 |
7,034 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-05-11 |
4 |
S |
$19.58 |
$42,023 |
D/D |
(2,146) |
186,794 |
0 |
% |
|
| BCRX |
Biocryst Pharmaceuticals ... |
Director |
• • – |
2020-08-31 |
4 |
A |
$4.15 |
$9,997 |
D/D |
2,409 |
28,613 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Dev |
• – – |
2008-07-07 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
31,165 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
SVP, Chief Business Officer |
• – – |
2009-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
48,416 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
SVP, Chief Business Officer |
• – – |
2009-06-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
50,916 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2010-05-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
35,087 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2010-06-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
37,587 |
0 |
- |
|
170 Records found
|
|
Page 2 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
